Seeking Alpha

Celldex (CLDX +5.2%) gains today as the company says its final results from its Phase 1 study of...

Celldex (CLDX +5.2%) gains today as the company says its final results from its Phase 1 study of CDX-301 supports the initiation of a pilot study in hematopoietic stem cell transplantation later this year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs